Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors
(Canagliflozin) may have a beneficial role on cardiac energetic efficiency.
Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected.
The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100
mg once daily, an interventional trial with a one-month washout period in between.
At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4),
each participant will undergo an identical postprandial metabolic study with positron
emission tomography (PET) and stable isotopic tracer methods.